期刊文献+

激素抵抗型前列腺癌的研究进展 被引量:17

Advances in Researches on Hormonal Refractory Prostate Cancer
下载PDF
导出
摘要 在我国,前列腺癌发病率逐年上升,晚期前列腺癌首选内分泌治疗,但相当一部分患者在内分泌治疗2-5年后病情进展为激素抵抗型前列腺癌(HRPC)。现就HRPC的分子生物学特点诊断标准、预测指标和治疗方法的研究进展作一综述,并展望HRPC的研究方向。 In China, the incidence of prostate cancer has been increasing in recent years. Hormonal therapy has been the mainstay of the therapeutic options for metastatic diseases for many years. But many metastatic tumors progress at a median of two to five years and become hormonal refractory prostate cancer(HRPC). This article summarizes in the advances of diagnostic criteria, molecular biological features, prediction markers, new therapeutic agents and further researches to be undertaken concerning HRPC.
出处 《中华男科学杂志》 CAS CSCD 2007年第1期57-60,共4页 National Journal of Andrology
关键词 前列腺癌 激素抵抗型 诊断 治疗 prostate cancer hormonal refractory diagnosis treatment
  • 相关文献

参考文献17

  • 1张世革,王益华,丁毅,吴烨.晚期前列腺癌联合雄激素阻断治疗的长期随访[J].中华男科学杂志,2005,11(10):770-771. 被引量:2
  • 2Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostare cancer[J]. N Engl J Med, 2004, 351(15) :1488-1490.
  • 3Heidenreich A, von Knobloch R, Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer[ J ].Eur Urol, 2001, 39(2) :121-130.
  • 4Chen CD, Welsbie D, Tran C, et al. Molecular determinants of resistance to antiandregen therapy[J]. Nat Med, 2004, 10( 1 ) :33-39.
  • 5Hasumi H, Ishiguro H, Nakamura M, et al. Neuroserpin (PI-12 ) is upregulated in high-grade prostate cancer and is associated with survival[J]. Int J Cancer, 2005, 115(6) : 911-916.
  • 6Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractary disease [ J ]. Endocr Relat Cancer, 2005, 12(1): 109-117.
  • 7Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer[J]. N Engl J Med, 2004, 351( 15 ) : 1513-1520.
  • 8Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351(15) :1502-1512.
  • 9Abratt RP, Brune D, Dimopoulos MA, et al. Randomised phase Ⅲ study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer[ J ].Ann Oncol, 2004, 15(11) : 1613-1621.
  • 10Rosenberg JE, Galsky MD, Rohs NC, et al. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after firstline epothilone-B analog ixabepilone ( BMS-247550 ) therapy [ J ].Cancer, 2006, 106( 1 ) :58-62.

二级参考文献8

  • 1Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials[ J ]. Lancet, 2000, 355 (9214): 1491-1498.
  • 2Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of locally advanced non-metastatic prostate cancer: a long-term follow-up[J]. J Urol, 1999, 161(2) :505-508.
  • 3Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer[J]. N Engl J Med, 1994, 330(4): 242-248.
  • 4Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden[J]. JAMA, 1997, 277(6) :467-471.
  • 5Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer[J]. N Engl J Med, 1998, 339(15) :1036-1042.
  • 6Kessler B, Albertsen P. The natural history of prostate cancer [J]. Urol Clin North Am, 2003, 30(2) :219-226.
  • 7Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiinstitutional update[J]. JAMA, 1997, 277(18): 1445-1451.
  • 8Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer[ J]. J Urol, 1993,150(1) :110-114.

共引文献1

同被引文献218

引证文献17

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部